J

Johnson & Johnson

Makes prescription drugs and medical devices

Technology Manager - Quality Systems Analyst

Full-TimePosted on 10/23/2026Deadline 10/30/26
$102k - $177.1k+ Long-term incentive program
Senior, Expert
Bachelor's, Master's
West Chester, PA, USA+4 moreMore locations: New Brunswick, NJ, USA | Raynham, MA, USA | Warsaw, IN, USA | Palm Beach Gardens, FL, USA
HybridHybrid work; up to 20% domestic travel across manufacturing and office sites.
ProductTechnical Product Management

About the job

Requirements
  • A bachelor's degree in Computer Science, Information Systems, Engineering, Life Sciences, Quality, Industrial Engineering, or a related discipline is required.
  • At least 8 years of progressive experience delivering and supporting enterprise quality systems or regulated business applications in a manufacturing or MedTech environment is required.
  • At least 2 years of experience leading teams, including managing performance, developing talent, and delivering results through others, is required.
  • Deep hands-on experience with enterprise quality management systems such as Veeva Vault QMS, TrackWise, ETQ, Sparta, or equivalent, across complaint, CAPA, nonconformance, and document control processes is required.
  • Strong working knowledge of GxP, 21 CFR Part 11, computer system validation, and data integrity (ALCOA+) requirements is required.
  • Experience owning a product roadmap and backlog for a regulated platform portfolio is required.
  • Experience defining quality metrics, analytics, and executive reporting from quality system data is required.
  • Experience integrating quality systems with ERP (SAP), PLM, and manufacturing systems is required.
  • Experience managing vendors, system integrators, or managed service partners against defined SLAs is required.
  • Strong stakeholder management and communication skills, with the ability to influence Quality and Regulatory leadership, are required.
  • English proficiency is required.
Responsibilities
  • Develop tactical and operational plans to achieve quality systems technology goals, and communicate plans to managers, supervisors, and individual contributors.
  • Develop, own, and execute the product roadmap for the enterprise quality systems portfolio, aligning platform capability to Quality and Regulatory strategy.
  • Prioritize and maintain the backlog for assigned quality platforms, balancing the requirements of Quality process owners, Regulatory, Manufacturing, and Technology stakeholders.
  • Lead the product functional design process based on detailed knowledge of quality system users, regulated processes, and platform technology.
  • Direct configuration, enhancement, and support of validated quality platforms covering complaint handling, CAPA, nonconformance, deviations, change control, document management, training records, and audit management.
  • Oversee analytics and reporting capability across quality data by defining metrics, dashboards, and trend analysis that provide Quality leadership visibility into record aging, cycle time, and compliance posture.
  • Ensure all platform changes follow computer system validation, change control, and documentation requirements consistent with GxP, 21 CFR Part 11, and data integrity (ALCOA+) expectations.
  • Direct integration of quality systems with ERP (SAP), PLM, manufacturing execution, and post-market surveillance systems.
  • Identify and deliver automation and AI-enabled improvement opportunities across quality processes, ensuring appropriate validation and human-in-the-loop controls.
  • Manage vendor and managed service partner relationships, including scope definition, quality of deliverables, and SLA performance.
  • Serve as the technology point of contact for internal, external, and regulatory audits and inspections, coordinating evidence, validation documentation, and remediation.
  • Assess quality systems implications of technology change, including platform migrations, ERP implementations, and separation or carve-out activity, and define requirements ahead of cutover.
  • Anticipate bottlenecks, provide escalation management, and build consensus by understanding stakeholder requirements and constraints.
  • Manage a team of individual contributors and/or supervisors, with accountability for effective performance management, capability building, and career development.
Desired Qualifications
  • A master's degree in Information Systems, Engineering, or Business Administration is preferred.
  • MedTech or medical device experience; familiarity with ISO 13485, EU MDR, and FDA QSR/QMSR requirements.
  • Experience leading quality systems migration, consolidation, or stand-up within a divestiture, carve-out, or standalone entity.
  • Experience applying Generative AI or LLM-enabled tooling to complaint triage, document review, or quality record analysis, with appropriate validation controls.
  • Familiarity with Agile/Scrum delivery and backlog-driven product management in a regulated context.
  • Proficiency with reporting and visualization tools such as Power BI and Tableau, and SQL for quality analytics.
  • Exposure to intelligent automation platforms such as RPA and workflow automation applied to quality operations.
  • Experience supporting regulatory inspections and external audits as a technology representative.
  • Familiarity with cloud platforms such as Azure and AWS and validated cloud application management.
  • Lean/Six Sigma, ASQ CQE/CQA, ITIL v4 Foundation, PMP, or relevant quality systems platform certification.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.